Biomarin Pharmaceutical BMRN
$60.41 −$1.01 (-1.64%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $60.02 -0.65%
Open$61.53
Prev close$61.42
Day range$59.84 – $62.01
Volume6.06M
Market cap$11.70B
P/E (TTM)–
Dividend yield–
BMRN Stock News
Headlines matching Biomarin Pharmaceutical or the BMRN ticker, most recent first.
- J.P. Morgan Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $86
- Piper Sandler Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $90 Positive
- Cantor Fitzgerald Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $86 Positive
- Guggenheim Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Cuts Target Price to $86 Negative
- BMO Capital Upgrades Biomarin Pharmaceutical(BMRN.US) to Buy Rating, Raises Target Price to $97 Positive
- Morgan Stanley Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $124
- Biomarin Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-Director Plenge Robert M
- Citi Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating
- Biomarin Pharmaceutical | 8-K: Current report
- Wells Fargo Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $80
- A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $70 to $124
- A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $62 to $124
- Stifel Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Maintains Target Price $70
- Piper Sandler Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $88
- TD Cowen Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $120
No comments yet — be the first to weigh in on BMRN.
Sign in to join the discussion.